ABSTRACT
The recently detected Omicron BA.2.86 lineage contains more than 30 amino acid mutations relative to BA.2. BA.2.86 and its JN.1 derivative evade neutralization by serum antibodies of fully vaccinated individuals. In this study, we elucidate epitopes driving the immune escape of BA.2.86 and JN.1 via pseudovirus neutralization. Thus, we have generated 33 BA.2.86 mutants, each reverting a single mutation back to BA.2. We use this library in an approach that we call reverse mutational scanning to define distinct neutralization titers against each epitope. Mutations within the receptor binding domain at K356T, V483Δ, and to a lesser extent N460K, A484K, and F486P enhance immune escape. Interestingly, 16insMPLF within the spike N-terminal domain and P621S within S1/S2 also significantly contribute to antibody escape of BA.2.86. Upon XBB.1.5 booster vaccination, neutralization titers against JN.1 and BA.2.86 improve considerably, and a residual immune escape is driven by 16insMPLF, N460K, E554K, and to a lesser extent P621S, and A484K.
EDITOR’S SUMMARY SARS COV2 Omicron lineage BA.2.86 has over 30 mutations compared to the parental BA.2 lineage. Here Bdeir and colleagues apply reverse mutational scanning to determine which among these mutations present in Omicron BA.2.86 are epitopes linked to immune escape from antibody recognition.
Competing Interest Statement
L.C-S. served as an advisor to Sanofi unrelated to this work. G.M.N.B. served as advisor for Moderna unrelated to this work, A.D-J served as an advisor for Pfizer unrelated to this work, S.P. and M.H. conducted contract research (testing of vaccinee sera for neutralizing activity against SARS-CoV-2) for Valneva unrelated to this work. S.P. served as advisor for BioNTech, unrelated to this work. H.J. served as advisor on COVID neutralization assays for WHO and CEPI, unrelated to this work. The other authors declare no competing interests.
Funding Statement
This research was funded by the Helmholtz Association through Helmholtz Campaign COVIPA (KA1-Co-02) to L.C-S. and EU-Partnering grant MCMVaccine (PIE-008) to L.C-S. and S.P. Funding to L.C-S and S.P. was also provided by the Ministry of Science and Culture of Lower Saxony, through the COFONI Network, flex fund projects 6FF22 and 10FF22. G.M.N.B. and A.D.-J. acknowledge funding from Ministry of Science and Culture of Lower Saxony (14-76103-184, COFONI Network, project 4LZF23), G.M.N.B. acknowledges funding by the European Regional Development Fund (ZW7-85151373), and A.D.-J. acknowledge funding by European Social Fund (ZAM5-87006761).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The collection of all plasma samples was approved by the research ethics committee of the Institutional Review Board of Hannover Medical School (8973 BO K 2020). All donors provided written consent for the blood donation and use for research purposes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
1
Blogs/Media
Author Videos